A detailed history of Great West Life Assurance CO transactions in Arcturus Therapeutics Holdings Inc. stock. As of the latest transaction made, Great West Life Assurance CO holds 6,050 shares of ARCT stock, worth $106,358. This represents 0.0% of its overall portfolio holdings.

Number of Shares
6,050
Previous 5,349 13.11%
Holding current value
$106,358
Previous $130,000 7.69%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$18.08 - $25.38 $12,674 - $17,791
701 Added 13.11%
6,050 $140,000
Q2 2024

Aug 12, 2024

BUY
$24.35 - $44.39 $20,867 - $38,042
857 Added 19.08%
5,349 $130,000
Q1 2024

May 13, 2024

BUY
$31.23 - $42.99 $13,366 - $18,399
428 Added 10.53%
4,492 $152,000
Q4 2023

Feb 13, 2024

SELL
$17.71 - $32.97 $6,039 - $11,242
-341 Reduced 7.74%
4,064 $127,000
Q3 2023

Nov 14, 2023

BUY
$25.44 - $37.35 $46,428 - $68,163
1,825 Added 70.74%
4,405 $112,000
Q2 2023

Aug 10, 2023

SELL
$23.94 - $32.36 $2,370 - $3,203
-99 Reduced 3.7%
2,580 $74,000
Q1 2023

May 12, 2023

BUY
$14.72 - $23.97 $9,067 - $14,765
616 Added 29.86%
2,679 $64,000
Q4 2022

Feb 10, 2023

BUY
$14.14 - $23.06 $3,492 - $5,695
247 Added 13.6%
2,063 $35,000
Q3 2022

Nov 01, 2022

BUY
$13.05 - $22.13 $23,698 - $40,188
1,816 New
1,816 $27,000
Q2 2022

Aug 09, 2022

BUY
$12.26 - $31.17 $2,280 - $5,797
186 Added 12.71%
1,649 $26,000
Q1 2022

May 12, 2022

BUY
$17.64 - $39.57 $2,646 - $5,935
150 Added 11.42%
1,463 $41,000
Q4 2021

Feb 14, 2022

BUY
$34.2 - $47.56 $4,959 - $6,896
145 Added 12.41%
1,313 $48,000
Q2 2020

Aug 17, 2020

BUY
$12.66 - $58.27 $14,786 - $68,059
1,168 New
1,168 $54,000

Others Institutions Holding ARCT

About Arcturus Therapeutics Holdings Inc.


  • Ticker ARCT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 26,576,400
  • Market Cap $467M
  • Description
  • Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lun...
More about ARCT
Track This Portfolio

Track Great West Life Assurance CO Portfolio

Follow Great West Life Assurance CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Great West Life Assurance CO , based on Form 13F filings with the SEC.

News

Stay updated on Great West Life Assurance CO with notifications on news.